Medicines Crushes Earnings Estimates
Medicines (NAS: MDCO) reported earnings on Feb. 20. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Medicines beat expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share expanded significantly. GAAP earnings per share grew.
Gross margins increased, operating margins expanded, net margins contracted.
Medicines booked revenue of $159.5 million. The five analysts polled by S&P Capital IQ wanted to see a top line of $145.1 million on the same basis. GAAP reported sales were 21% higher than the prior-year quarter's $132.2 million.
EPS came in at $0.78. The three earnings estimates compiled by S&P Capital IQ predicted $0.51 per share. Non-GAAP EPS of $0.78 for Q4 were 117% higher than the prior-year quarter's $0.36 per share. GAAP EPS of $0.38 for Q4 were 8.6% higher than the prior-year quarter's $0.35 per share.
For the quarter, gross margin was 67.3%, 60 basis points better than the prior-year quarter. Operating margin was 22.8%, 760 basis points better than the prior-year quarter. Net margin was 13.0%, 180 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $157.6 million. On the bottom line, the average EPS estimate is $0.43.
Next year's average estimate for revenue is $655.1 million. The average EPS estimate is $1.94.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 139 members out of 154 rating the stock outperform, and 15 members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Medicines a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medicines is outperform, with an average price target of $31.00.
- Add Medicines to My Watchlist.
The article Medicines Crushes Earnings Estimates originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.